{"title":"BATF3作为外周t细胞淋巴瘤生物标记基因的鉴定和验证。","authors":"Yidong Zhu, Jun Liu, Ting Zhang","doi":"10.2174/0109298673367678250414061434","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological malignancies. Treatment options are limited and often unsatisfactory, leading to a poor prognosis in most subtypes.</p><p><strong>Objective: </strong>his study aimed to identify potential biomarker genes for PTCL and to explore the underlying mechanisms by integrating machine learning, Mendelian Randomization (MR), and experimental validation.</p><p><strong>Methods: </strong>Microarray datasets (GSE6338, GSE14879, and GSE59307) were downloaded from the Gene Expression Omnibus database. Differential expression analysis was conducted to identify the Differentially Expressed Genes (DEGs) between patients with PTCL and controls. A machine learning algorithm was then used to further refine the selection of characteristic genes for PTCL. We integrated genome-wide association studies data with expression quantitative trait loci data to identify genes with potential causal relationships to PTCL. Functional analysis was performed to explore underlying mechanisms. Finally, the identified gene was validated in clinical samples from patients with PTCL and controls.</p><p><strong>Results: </strong>Based on 60 DEGs, the least absolute shrinkage and selection operator algorithm identified nine characteristic genes for PTCL. MR analysis revealed 203 genes with causal effects on PTCL, ultimately identifying one co-expressed gene: Basic Leucine Zipper ATF-like Transcription Factor 3 (BATF3). It demonstrated good predictive performance across various PTCL subtypes, with AUC values ranging from 0.7 to 1. Functional analysis suggested that BATF3 may play a role in PTCL through immune- related pathways. Experimental validation using clinical samples further suggested the potential of this biomarker gene in PTCL.</p><p><strong>Conclusion: </strong>By combining machine learning, MR, and experimental validation, we identified and validated BATF3 as a promising biomarker of PTCL. These findings provide insights into the molecular mechanisms underlying PTCL and may inform the development of effective treatment strategies for this disease.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Identification and Validation of BATF3 as a Promising Biomarker Gene for Peripheral T-cell Lymphoma.\",\"authors\":\"Yidong Zhu, Jun Liu, Ting Zhang\",\"doi\":\"10.2174/0109298673367678250414061434\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological malignancies. Treatment options are limited and often unsatisfactory, leading to a poor prognosis in most subtypes.</p><p><strong>Objective: </strong>his study aimed to identify potential biomarker genes for PTCL and to explore the underlying mechanisms by integrating machine learning, Mendelian Randomization (MR), and experimental validation.</p><p><strong>Methods: </strong>Microarray datasets (GSE6338, GSE14879, and GSE59307) were downloaded from the Gene Expression Omnibus database. Differential expression analysis was conducted to identify the Differentially Expressed Genes (DEGs) between patients with PTCL and controls. A machine learning algorithm was then used to further refine the selection of characteristic genes for PTCL. We integrated genome-wide association studies data with expression quantitative trait loci data to identify genes with potential causal relationships to PTCL. Functional analysis was performed to explore underlying mechanisms. Finally, the identified gene was validated in clinical samples from patients with PTCL and controls.</p><p><strong>Results: </strong>Based on 60 DEGs, the least absolute shrinkage and selection operator algorithm identified nine characteristic genes for PTCL. MR analysis revealed 203 genes with causal effects on PTCL, ultimately identifying one co-expressed gene: Basic Leucine Zipper ATF-like Transcription Factor 3 (BATF3). It demonstrated good predictive performance across various PTCL subtypes, with AUC values ranging from 0.7 to 1. Functional analysis suggested that BATF3 may play a role in PTCL through immune- related pathways. Experimental validation using clinical samples further suggested the potential of this biomarker gene in PTCL.</p><p><strong>Conclusion: </strong>By combining machine learning, MR, and experimental validation, we identified and validated BATF3 as a promising biomarker of PTCL. These findings provide insights into the molecular mechanisms underlying PTCL and may inform the development of effective treatment strategies for this disease.</p>\",\"PeriodicalId\":10984,\"journal\":{\"name\":\"Current medicinal chemistry\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-05-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current medicinal chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0109298673367678250414061434\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0109298673367678250414061434","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Identification and Validation of BATF3 as a Promising Biomarker Gene for Peripheral T-cell Lymphoma.
Background: Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological malignancies. Treatment options are limited and often unsatisfactory, leading to a poor prognosis in most subtypes.
Objective: his study aimed to identify potential biomarker genes for PTCL and to explore the underlying mechanisms by integrating machine learning, Mendelian Randomization (MR), and experimental validation.
Methods: Microarray datasets (GSE6338, GSE14879, and GSE59307) were downloaded from the Gene Expression Omnibus database. Differential expression analysis was conducted to identify the Differentially Expressed Genes (DEGs) between patients with PTCL and controls. A machine learning algorithm was then used to further refine the selection of characteristic genes for PTCL. We integrated genome-wide association studies data with expression quantitative trait loci data to identify genes with potential causal relationships to PTCL. Functional analysis was performed to explore underlying mechanisms. Finally, the identified gene was validated in clinical samples from patients with PTCL and controls.
Results: Based on 60 DEGs, the least absolute shrinkage and selection operator algorithm identified nine characteristic genes for PTCL. MR analysis revealed 203 genes with causal effects on PTCL, ultimately identifying one co-expressed gene: Basic Leucine Zipper ATF-like Transcription Factor 3 (BATF3). It demonstrated good predictive performance across various PTCL subtypes, with AUC values ranging from 0.7 to 1. Functional analysis suggested that BATF3 may play a role in PTCL through immune- related pathways. Experimental validation using clinical samples further suggested the potential of this biomarker gene in PTCL.
Conclusion: By combining machine learning, MR, and experimental validation, we identified and validated BATF3 as a promising biomarker of PTCL. These findings provide insights into the molecular mechanisms underlying PTCL and may inform the development of effective treatment strategies for this disease.
期刊介绍:
Aims & Scope
Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.